



Effect of Preoperative Endoscopic Biliary Drainage on Postoperative Outcomes of Resectable Pancreaticobiliary Malignancies with Obstructive Jaundice

A Single-center Retrospective Study

Sureshkumar S, Sriram V S, Sudharsanan S, Vijayakumar C, Kalayarasan R, Pazhanivel Mohan, Keerthi A R, Abdul Basith K M
JIPMER, Pondicherry, India



SAGES 2026

Study Objectives



Primary Objective: 30-Day Complication Analysis

The study aimed to compare postoperative outcomes including Surgical Site Infection (SSI), Pancreatic Fistula (PDPF), Delayed Gastric Emptying (DGE), hemorrhage, and mortality between PBD and Direct Surgery groups.



Secondary Objectives: Risk Identification

Evaluation of stenting related complications, the impact of the time interval between PBD and surgery, and determining a definitive bilirubin threshold for PBD benefit.

Retrospective Cohort (2018-2023)



A single-center study conducted at JIPMER, India, involving 190 patients with resectable pancreaticobiliary cancers.

METHODOLOGY AND DATA COLLECTION

Initial Cohort

190 eligible patients underwent successful Pancreaticoduodenectomy (PD).

Direct Surgery Group (n=122)

52 patients presented without jaundice, while 70 patients presented with jaundice and were included in the primary comparative analysis.

PBD + Surgery Group (n=88)

68 patients underwent preoperative biliary stenting followed by surgery and were considered for the analysis.

Increased Risk of Surgical Site Infection (SSI)

Outcome	PBD Group	Direct Surgery Group	p-value
SSI Rate	78%	52.8%	0.018
Positive Intraoperative Bile Cultures	55.8%	27.1%	0.001

Higher Rates of Contaminated Bile

PBD Group

55.8%

Positive Intraoperative Bile Cultures

Direct Surgery Group


27.1%

Positive Intraoperative Bile Cultures




(p=0.001)

Indications for PBD (n=68 Patients)



CORE RESULTS


12.1 mg/dL Bilirubin Cut-off



No Benefit Below Threshold

PBD offers no clinical advantage or reduction in serious complications for patients with a serum bilirubin less than 12.1 mg/dL.

Prolonged Stenting Risk



THE THRESHOLD & CONCLUSION



PBD as an Independent Risk Factor

Routine use of PBD is an independent risk factor for SSI and should be avoided if bilirubin is below the 12.1 mg/dL threshold.

Reserve PBD for Specific Indications



Severe illness



Chemotherapy



Complex surgery

Clinical practice should limit PBD to cases of severe cholangitis, patients requiring neoadjuvant therapy, or those needing extended preoperative optimization.